149 related articles for article (PubMed ID: 15701837)
1. The thioredoxin-1 inhibitor 1-methylpropyl 2-imidazolyl disulfide (PX-12) decreases vascular permeability in tumor xenografts monitored by dynamic contrast enhanced magnetic resonance imaging.
Jordan BF; Runquist M; Raghunand N; Gillies RJ; Tate WR; Powis G; Baker AF
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):529-36. PubMed ID: 15701837
[TBL] [Abstract][Full Text] [Related]
2. The antitumor thioredoxin-1 inhibitor PX-12 (1-methylpropyl 2-imidazolyl disulfide) decreases thioredoxin-1 and VEGF levels in cancer patient plasma.
Baker AF; Dragovich T; Tate WR; Ramanathan RK; Roe D; Hsu CH; Kirkpatrick DL; Powis G
J Lab Clin Med; 2006 Feb; 147(2):83-90. PubMed ID: 16459166
[TBL] [Abstract][Full Text] [Related]
3. The thioredoxin redox inhibitors 1-methylpropyl 2-imidazolyl disulfide and pleurotin inhibit hypoxia-induced factor 1alpha and vascular endothelial growth factor formation.
Welsh SJ; Williams RR; Birmingham A; Newman DJ; Kirkpatrick DL; Powis G
Mol Cancer Ther; 2003 Mar; 2(3):235-43. PubMed ID: 12657718
[TBL] [Abstract][Full Text] [Related]
4. Effects of the thioredoxin-1 inhibitor PX-12 on blood-brain barrier permeability in the early stage of focal cerebral ischemia.
Chi OZ; Barsoum S; Grayson J; Liu X; Weiss HR
Pharmacology; 2013; 92(3-4):175-81. PubMed ID: 24060905
[TBL] [Abstract][Full Text] [Related]
5. Dynamic contrast-enhanced and diffusion MRI show rapid and dramatic changes in tumor microenvironment in response to inhibition of HIF-1alpha using PX-478.
Jordan BF; Runquist M; Raghunand N; Baker A; Williams R; Kirkpatrick L; Powis G; Gillies RJ
Neoplasia; 2005 May; 7(5):475-85. PubMed ID: 15967100
[TBL] [Abstract][Full Text] [Related]
6. Early antiangiogenic activity of SU11248 evaluated in vivo by dynamic contrast-enhanced magnetic resonance imaging in an experimental model of colon carcinoma.
Marzola P; Degrassi A; Calderan L; Farace P; Nicolato E; Crescimanno C; Sandri M; Giusti A; Pesenti E; Terron A; Sbarbati A; Osculati F
Clin Cancer Res; 2005 Aug; 11(16):5827-32. PubMed ID: 16115922
[TBL] [Abstract][Full Text] [Related]
7. Experimental study on thioredoxin redox inhibitor 1-methylpropyl 2-imidazolyl disulfide promoting apoptosis of multiple myeloma cells in vitro and in vivo.
Lin QD; Liu LN; Liu XY; Yan Y; Fang BJ; Zhang YL; Zhou J; Li YF; Zuo WL; Song YP
Eur Rev Med Pharmacol Sci; 2022 Feb; 26(4):1283-1292. PubMed ID: 35253185
[TBL] [Abstract][Full Text] [Related]
8. A phase IB trial of 24-hour intravenous PX-12, a thioredoxin-1 inhibitor, in patients with advanced gastrointestinal cancers.
Baker AF; Adab KN; Raghunand N; Chow H; Stratton SP; Squire SW; Boice M; Pestano LA; Kirkpatrick DL; Dragovich T
Invest New Drugs; 2013 Jun; 31(3):631-641. PubMed ID: 22711542
[TBL] [Abstract][Full Text] [Related]
9. Thioredoxin-1 inhibitor, 1-methylpropyl 2-imidazolyl disulfide, inhibits the growth, migration and invasion of colorectal cancer cell lines.
Wang F; Lin F; Zhang P; Ni W; Bi L; Wu J; Jiang L
Oncol Rep; 2015 Feb; 33(2):967-73. PubMed ID: 25483731
[TBL] [Abstract][Full Text] [Related]
10. AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging.
Wilmes LJ; Pallavicini MG; Fleming LM; Gibbs J; Wang D; Li KL; Partridge SC; Henry RG; Shalinsky DR; Hu-Lowe D; Park JW; McShane TM; Lu Y; Brasch RC; Hylton NM
Magn Reson Imaging; 2007 Apr; 25(3):319-27. PubMed ID: 17371720
[TBL] [Abstract][Full Text] [Related]
11. Macromolecular dynamic contrast-enhanced (DCE)-MRI detects reduced vascular permeability in a prostate cancer bone metastasis model following anti-platelet-derived growth factor receptor (PDGFR) therapy, indicating a drop in vascular endothelial growth factor receptor (VEGFR) activation.
Dafni H; Kim SJ; Bankson JA; Sankaranarayanapillai M; Ronen SM
Magn Reson Med; 2008 Oct; 60(4):822-33. PubMed ID: 18816866
[TBL] [Abstract][Full Text] [Related]
12. Anti-angiogenic Effects of Bumetanide Revealed by DCE-MRI with a Biodegradable Macromolecular Contrast Agent in a Colon Cancer Model.
Malamas AS; Jin E; Zhang Q; Haaga J; Lu ZR
Pharm Res; 2015 Sep; 32(9):3029-43. PubMed ID: 25840948
[TBL] [Abstract][Full Text] [Related]
13. Thioredoxin-1 inhibitor PX-12 induces human acute myeloid leukemia cell apoptosis and enhances the sensitivity of cells to arsenic trioxide.
Tan Y; Bi L; Zhang P; Wang F; Lin F; Ni W; Wu J; Jiang L
Int J Clin Exp Pathol; 2014; 7(8):4765-73. PubMed ID: 25197347
[TBL] [Abstract][Full Text] [Related]
14. A phase I trial of PX-12, a small-molecule inhibitor of thioredoxin-1, administered as a 72-hour infusion every 21 days in patients with advanced cancers refractory to standard therapy.
Ramanathan RK; Stephenson JJ; Weiss GJ; Pestano LA; Lowe A; Hiscox A; Leos RA; Martin JC; Kirkpatrick L; Richards DA
Invest New Drugs; 2012 Aug; 30(4):1591-6. PubMed ID: 21863237
[TBL] [Abstract][Full Text] [Related]
15. Permeability to macromolecular contrast media quantified by dynamic MRI correlates with tumor tissue assays of vascular endothelial growth factor (VEGF).
Cyran CC; Sennino B; Fu Y; Rogut V; Shames DM; Chaopathomkul B; Wendland MF; McDonald DM; Brasch RC; Raatschen HJ
Eur J Radiol; 2012 May; 81(5):891-6. PubMed ID: 21889860
[TBL] [Abstract][Full Text] [Related]
16. Parallel syntheses of disulfide inhibitors of the thioredoxin redox system as potential antitumor agents.
Kirkpatrick DL; Watson S; Kunkel M; Fletcher S; Ulhaq S; Powis G
Anticancer Drug Des; 1999 Oct; 14(5):421-32. PubMed ID: 10766297
[TBL] [Abstract][Full Text] [Related]
17. Preclinical evaluation of tumor microvascular response to a novel antiangiogenic/antitumor agent RO0281501 by dynamic contrast-enhanced MRI at 1.5 T.
Muruganandham M; Lupu M; Dyke JP; Matei C; Linn M; Packman K; Kolinsky K; Higgins B; Koutcher JA
Mol Cancer Ther; 2006 Aug; 5(8):1950-7. PubMed ID: 16928815
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of vascular endothelial growth factor 165 drives peritumor interstitial convection and induces lymphatic drain: magnetic resonance imaging, confocal microscopy, and histological tracking of triple-labeled albumin.
Dafni H; Israely T; Bhujwalla ZM; Benjamin LE; Neeman M
Cancer Res; 2002 Nov; 62(22):6731-9. PubMed ID: 12438274
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of the thioredoxin system by PX-12 (1-methylpropyl 2-imidazolyl disulfide) impedes HIV-1 infection in TZM-bl cells.
Lundberg M; Mattsson Å; Reiser K; Holmgren A; Curbo S
Sci Rep; 2019 Apr; 9(1):5656. PubMed ID: 30948772
[TBL] [Abstract][Full Text] [Related]
20. Thioredoxin Confers Intrinsic Resistance to Cytostatic Drugs in Human Glioma Cells.
Haas B; Schütte L; Wos-Maganga M; Weickhardt S; Timmer M; Eckstein N
Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30248944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
